secwatch.observer — SEC 8-K summary
======================================

Issuer:     CONMED Corp (CNMD)
CIK:        0000816956
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001174947-25-001185
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025
--------------------------------------------------------------------------

- Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.
- He serves on Corporate Governance & Nominating and Strategy Committees.
- Kelderman is President & CEO of Bio-Techne (TECH) since February 2024.
- Granted prorated equity valued at ~$134,766 (500 RSUs + options for 6,227 shares).
- Prior roles include Thermo Fisher Scientific and Becton Dickinson.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/0001174947-25-001185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/816956/000117494725001185/form8k-34670_cnmd.htm
  HTML page:      https://secwatch.observer/filing/0001174947-25-001185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer